Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis

Journal of Alzheimer's Disease

Volumn 38, Issue 4, 2014, Pages 767-786

  Paganetti, Paolo ^a   Antoniello, Katia ^a   Devraj, Kavi ^b   Toni, Nicolas ^a,f   Kieran, Dairin ^a,g   Madani, Rime ^a   Pihlgren, Maria ^a   Adolfsson, Oskar ^a   Froestl, Wolfgang ^a   Schrattenholz, André ^c   Liebner, Stefan ^b   Havas, Daniel ^d   Windisch, Manfred ^d   Cirrito, John R ^e   Pfeifer, Andrea ^a   Muhs, Andreas ^a  

^a AC IMMUNE SA   (Switzerland)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c PROTEOSYS AG   (Germany)

^d QPS Austria   (Austria)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g IQVIA   (United States)

Author keywords

Amyloid peptides; A brain efflux; A clearance; A homeostasis; A PP transgenic mice; Drug treatment; Muscarinic receptors; Plaque deposition

Indexed keywords

ACI 91; AMYLOID BETA PROTEIN; DARIFENACIN; PIRENZEPINE; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN AMYLOIDOSIS; BRAIN DISEASE; CONTROLLED STUDY; DOWN REGULATION; DRUG HALF LIFE; EFFUSION; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; UPREGULATION;

AMYLOID-Β PEPTIDES; AΒ BRAIN EFFLUX; AΒ CLEARANCE; AΒ HOMEOSTASIS; AΒPP TRANSGENIC MICE; DRUG TREATMENT; MUSCARINIC RECEPTORS; PLAQUE DEPOSITION;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCARINIC ANTAGONISTS; PHENOTYPE; PIRENZEPINE; RECEPTORS, MUSCARINIC;

EID: 84890471966     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131091     Document Type: Article

References (65)

1. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci 13, 812-818.
2. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15, 349-357.
3. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
4. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34, 185-204.
5. Bertram L, Tanzi RE (2012) The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci 107, 79-100.
6. Kitazawa M, Medeiros R, Laferla FM (2012) Transgenic mouse models of Alzheimer disease: Developing a better model as a tool for therapeutic interventions. Curr Pharm Des 18, 1131-1147.
7. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
8. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
9. Kurz A, Perneczky RJ (2011) Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 24 (Suppl 2), 61-73.
10. Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2, pii:a011452.
11. Zlokovic BV (2004) Clearing amyloid through the bloodbrain barrier. J Neurochem 89, 807-811.
12. Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E, Masliah E (2002) Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci 22, 9298-9304.
13. XuG, Karch C, Li N, Lin N, Fromholt D, GonzalesV, Borchelt DR (2008) Receptor-associated protein (RAP) plays a central role in modulating Abeta deposition in APP/PS1 transgenic mice. PLoS One 3, e3159.
14. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-Demotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP 1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17, 553-570.
15. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106, 1159-1166.
16. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron 43, 605-608.
17. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290.
18. Deane RJ (2012) Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 4, 915-925.
19. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor related protein in liver. Proc Natl Acad Sci U S A 109, 3510-3515.
20. Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller- Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez- Agosti C, Nitsch RM (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10, 1-6.
21. FisherA(2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: Perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 120 (Suppl 1), 22-33.
22. Kenakin T, Boselli C (1989) Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: Resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. J Pharmacol Exp Ther 250, 944-952.
23. Caulfield MP, Birdsall NJ (1998) Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50, 279-290.
24. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, Mathews PM, Jucker M (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940-946.
25. Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E (2001) Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 66, 573-582.
26. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381.
27. Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuipéri C, Laenen I, Caluwaerts N, Moechars D, Checler F, Vanderstichele H, Van Leuven F (2000) Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci 20, 6452-6458.
28. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
29. Cui M, Ono M, Kimura H, Kawashima H, Liu BL, Saji H (2011) Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of β-amyloid plaques in Alzheimer's disease. Nucl Med Biol 38, 313-320.
30. Jankowsky JL, Slunt HH, Ratovitski T, JenkinsNA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng 17, 157-165.
31. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23, 8844-8853.
32. Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR (2011) Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci 31, 11328-11337.
33. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr., Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R (2000) Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 275, 34086-34091.
34. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ (2011) Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymalAβ during age-related plaque formation. J Neurosci 31, 15861-15869.
35. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol 183, 409-417.
36. Fisher J, Devraj K, Ingram J, Slagle-Webb B, Madhankumar AB, Liu X, Klinger M, Simpson IA, Connor JR (2007) Ferritin: A novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol 293, C641-649.
37. Paolinelli R, Corada M, Devraj K, Ferrarini L, Artus C, Czupalla C, Rudini N, Luigi M, Engelhardt B, Couraud PO, Liebner S, Dejana E (2013) Wnt activation of immortalized brain endothelial cells as a tool for generating a standardized model of the blood-brain barrier in vitro. PLoS ONE 8, e70233.
38. ReissY, Hoch G, Deutsch U, Engelhardt B (1998) T cell interaction with ICAM-1-deficient endothelium in vitro: Essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells. Eur J Immunol 28, 3086-3099.
39. Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E, Fruttiger M, Taketo MM, Dimmeler S, Plate KH, Liebner S (2012) Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209, 1611-1627.
40. Abramowski D, Rabe S, Upadhaya AR, Reichwald J, Danner S, Staab D, Capetillo-Zarate E, Yamaguchi H, Saido TC, Wiederhold KH, Thal DR, Staufenbiel M (2012) Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology. J Neurosci 32, 1273-1283.
41. Carmine AA and Brogden RN (1985) Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30, 85-126.
42. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
43. Kakee A, Terasaki T, SugiyamaY(1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 227, 1550-1559.
44. Kusuhara H, Terasaki T, Sugiyama Y (2003) Brain efflux index method. Characterization of efflux transport across the blood-brain barrier. Methods Mol Med 89, 219-231.
45. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 35, 546-551.
46. Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Klünemann HH, Schuierer G, Schlachetzki F (2012) Amyloid-Β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514-523.
47. Lyck R, Ruderisch N, Moll AG, Steiner O, Cohen CD, Engelhardt B, Makrides V, Verrey F (2009) Culture-induced changes in blood-brain barrier transcriptome: Implications for amino-acid transporters in vivo. J Cereb Blood Flow Metab 29, 1491-1502.
48. Fukamauchi F, Saunders PA, Hough C, Chuang DM (1993) Agonist-induced down-regulation and antagonist-induced upregulation of m2- and m3-muscarinic acetylcholine receptor mRNA and protein in cultured cerebellar granule cells. Mol Pharmacol 44, 940-949.
49. Yamada K, Hashimoto T, Yabuki C, Nagae Y, Tachikawa M, Strickland DK, Liu Q, Bu G, Basak JM, Holtzman DM, Ohtsuki S, Terasaki T, Iwatsubo (2008) The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 283, 34554-34562.
50. Kobayashi S, Kyui S, Yoshida T, Nagakura A, Oiwa Y, Matsumura R, Kohei H (1981) Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. Arzneimittelforschung 31, 679-690.
51. WuW, Saunders RC, Mishkin M, Turchi J (2012) Differential effects of m1 and m2 receptor antagonists in perirhinal cortex on visual recognition memory in monkeys. Neurobiol Learn Mem 98, 41-46.
52. Aura J, Sirviö J, Riekkinen P Jr. (1997) Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. Eur J Pharmacol 333, 129-134.
53. Ukai M, Shinkai N, Kameyama T (1995) Cholinergic receptor agonists inhibit Pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse. Gen Pharmacol 26, 1529-1532.
54. Kittelberger KA, Piazza F, Tesco G, Reijmers LG (2012) Natural amyloid-beta oligomers acutely impair the formation of a contextual fear memory in mice. PLoS One 7, e29940.
55. Bubser M, Byun N, Wood MR, Jones CK (2012) Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol 208, 121-166.
56. Potter PE (2010) Investigational medications for treatment of patients with Alzheimer disease. J Am Osteopath Assoc 110, S27-S36.
57. Caccamo A, Fisher A, LaFerla FM (2009) M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 6, 112-117.
58. Haab F (2005) Darifenacin for the treatment of overactive bladder. Womens Health 1, 331-343.
59. Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K (2007) Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 30, 54-58.
60. ElhusseinyA, Cohen Z, Olivier A, Stanimirović DB, Hamel E (1999) Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: Identification and cellular localization. J Cereb Blood Flow Metab 19, 794-802.
61. Rubin LL, Hall DE, Porter S, Barbu K, Cannon C, Horner HC, Janatpour M, Liaw CW, Manning K, Morales J, Tanner LI, Tomaselli KJ and Bard F (1991) A cell culture model of the blood-brain barrier. J Cell Biol 115, 1725-17235.
62. Willis CL, Meske DS, Davis TP (2010) Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab 30, 1847-1859.
63. Rigor RR, Hawkins BT, Miller DS (2010) Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases Pglycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab 30, 1373-1383.
64. Moro V, Kacem K, Springhetti V, Seylaz J, Lasbennes F (1995) Microvessels isolated from brain: Localization of muscarinic sites by radioligand binding and immunofluorescent techniques. J Cereb Blood Flow Metab 15, 1082-1092.
65. Iliff JJ, Wang M, Liao Y, Plogg BA, PengW, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard N (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including Amyloid. Sci Transl Med 4, 147ra111.